



# Learning and education: Stakeholders in healthcare



Translating evidence relevant for enhancing patient care into respective learning interventions in disease areas



References:

1. Allen T., Donde N., Hofstädter-Thalman E., Keijser S., Moy V., Murama J.J., Kellner T. 2017. Framework for industry engagement and quality principles for industry-provided medical education in Europe. Journal of European CME. <http://dx.doi.org/10.1080/21614083.2017.1348876>
2. IFPMA Note for Guidance on Continuous Medical Education. 2018. <https://www.ifpma.org/resource-centre/ifpma-note-for-guidance-on-continuing-medical-education/>

# For discussion

- ▶ Question 1: Is there common ground between pharma and that of other medical educational professionals (in terms of what they want to achieve)?
- ▶ Question 2: What do you see as the risks of pharma being involved in the provision of lifelong learning to HCPs?
- ▶ Question 3: If you were to give advice to pharma regarding their involvement in lifelong learning, what would that be?

# Different Types of Medical Education in Europe

Skopowski et al. presented at #9ECF (2016)

